FDA Grants Fast Track Designation to Vir Biotechnology’s VIR-5500

Key Facts

1The U.S. FDA granted Fast Track designation to VIR-5500 for the treatment of late-line metastatic castration-resistant prostate cancer.

The U.S. Food and Drug Administration granted Fast Track designation to VIR-5500, an investigational T-cell engager developed by Vir Biotechnology for the treatment of metastatic castration-resistant prostate cancer. Business Wire reported that the designation is intended to facilitate the development and expedite the review of drugs designed to treat serious conditions and fill unmet medical needs.

Vir Biotechnology (VIR) closed at $11.52 on October 7, 2026, while Astellas Pharma (ALPMF) closed at $14.25 on the same date. This regulatory milestone represents a positive development for the company's pipeline, as the Fast Track status potentially shortens the time to market for this key investigational asset.